Private equity firms are competing to acquire a 25% [1] equity stake in Cloudnine, India's largest maternity and paediatric hospital chain [1, 2].
The deal signals a significant shift in ownership for the healthcare provider as it seeks capital to fund international growth. The competition among global investment firms highlights the increasing attractiveness of specialized healthcare assets within the Indian market.
Warburg Pincus, KKR, and TPG are among the primary suitors vying for the stake [1, 2]. Other interested parties include Advent, CVC, Permira, and Kedaara [1, 2]. The bidding process comes as existing investor True North plans a full exit from the company [2].
The transaction values Cloudnine at approximately $1 billion [1], which is equivalent to ₹10,000 crore [2]. This valuation reflects the company's scale as a nationwide operator in India [1, 2].
Financial data for the 2026 fiscal year shows Cloudnine reported revenue of ₹2,000 crore [4]. The company also recorded an EBITDA of ₹300 crore [4] for the same period.
Cloudnine is currently targeting an expansion of its services into the Middle East [2]. The infusion of new private equity capital is intended to support this strategic move into new geographic markets, a transition that requires significant liquidity and operational expertise.
While the specific timeline for the closing of the deal has not been disclosed, the presence of multiple global PE giants suggests a competitive bidding environment. The transition from True North to a new lead investor will likely determine the pace of the chain's international rollout [2].
“Private equity firms are competing to acquire a 25% equity stake in Cloudnine.”
The interest from top-tier global firms like KKR and Warburg Pincus underscores a broader trend of 'platformization' in Indian healthcare, where investors seek dominant market leaders in specific niches—such as maternity care—to scale them internationally. Cloudnine's move into the Middle East suggests it is attempting to evolve from a domestic provider into a regional healthcare brand, leveraging its high EBITDA margins to attract institutional capital.
